CIBR Leads the Charge in Brain-Computer Interface Technology in China
CIBR's Progress in Brain-Computer Interface Technology
A Chinese brain-computer interface (BCI) company, CIBR, has reported positive outcomes from its recent human implants. This advancement is pivotal as China gears up for the broader commercialisation of BCI technologies. The Beinao No 1, a semi-invasive BCI system developed in Beijing, achieved its first three human implants recently, matching the efforts of Neuralink.
Government Support for BCI Market
- In Hubei province, the government has established the first pricing guidelines for invasive BCI operations, setting a fee of 6,552 yuan ($902) per procedure.
- Removals of such implants will cost approximately 3,139 yuan, while non-invasive options will be priced at 966 yuan.
Impact on Patients with Disabilities
The Beinao system has enabled paralysed patients to exert mind control for operating computers and robotic arms. Additionally, it successfully decodes the Chinese speech of patients with speech disorders.
Future Goals and Regulatory Challenges
- The CIBR aims to implant brain chips in 13 patients this year.
- Plans to conduct formal clinical trials on around 50 patients in the next year are underway, pending regulatory approvals.
At the Zhongguancun Forum, CIBR director Luo Minmin expressed optimism about moving closer to commercial medical products to help those with paralysis.
As the BCI industry grows, companies like Shanghai-based StairMed have also recently raised significant investments, aiding in the competitive landscape against established players like Neuralink.
For further details, please visit the original source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.